Drs Banu Arun and Nadine Tung discuss access to genetic counseling and germline genetic testing, and their earlier incorporation into the multidisciplinary management of patients with breast cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982646). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Stage IV (Advanced or Metastatic) Breast Cancer https://nbcf.org.au/about-breast-cancer/diagnosis/stage-4-advanced-or-metastatic-breast-cancer/

Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management https://pubmed.ncbi.nlm.nih.gov/31634909/

Breast Cancer https://emedicine.medscape.com/article/1947145-overview

PIK3CA Gene https://medlineplus.gov/genetics/gene/pik3ca/#synonyms

ESR1 Mutations in Breast Cancer https://pubmed.ncbi.nlm.nih.gov/31318440/

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

BRCA Gene Mutations: Cancer Risk and Genetic Testing https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#what-are-brca1-and-brca2

PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/

Consensus Guideline on Genetic Testing for Hereditary Breast Cancer https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf

Triple Negative Breast Cancer: A Thorough Review of Biomarkers https://pubmed.ncbi.nlm.nih.gov/31927455/

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 https://pubmed.ncbi.nlm.nih.gov/34794122/

Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/28578601/

Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/30110579/

Olaparib https://reference.medscape.com/drug/lynparza-olaparib-999934

Talazoparib https://reference.medscape.com/drug/talzenna-talazoparib-1000290

Efficacy of Platinum-Based and Non-Platinum-Based Drugs on Triple-Negative Breast Cancer: Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36242046/

Third-line Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/third-line-therapy

Management of Hormone Receptor-Positive, HER2-Negative Early Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32546323/

Endocrine Therapy for ER-Positive/HER2-Negative Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30056727/

The Emerging CDK4/6 Inhibitor for Breast Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/35251463/

Progression-Free Survival https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progression-free-survival

PARP1 https://www.mycancergenome.org/content/gene/parp1/

Platinum-Based Systematic Therapy in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35026309/

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/25847936/

Carboplatin in BRCA1/2-Mutated and Triple-Negative Breast Cancer BRCAness Subgroups: The TNT Trial https://pubmed.ncbi.nlm.nih.gov/29713086/

Taxanes for Adjuvant Treatment of Early Breast Cancer https://pubmed.ncbi.nlm.nih.gov/31476253/

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/32560564/

A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) https://pubmed.ncbi.nlm.nih.gov/30563931/

Myelodysplastic Syndrome (MDS) https://emedicine.medscape.com/article/207347-overview